The revenue beat and raised guidance support the growth thesis, but the GAAP EPS miss and declining adjusted EPS warrant caution. Watch for Digital Health margin progression and integration of recent acquisitions; the raised FCF guidance suggests improving cash generation. The stock may trade on the revenue/guidance strength versus the EPS disappointment.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $77.28entry
- T+1 · 3mo ago −1.22%α −0.90% · $76.34
- T+5 · 3mo ago −1.75%α −1.70% · $75.93
- T+20 · 2mo ago −6.87%α −5.96% · $71.97
- T+60 · 14d ago −5.31%α −2.89% · $73.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RadNet reported Q2 2026 revenue of $622.7M (+25% YoY), beating consensus of $609.3M, but GAAP EPS of $0.10 missed the $0.20 estimate by 50%. The company raised full-year Imaging Center guidance for revenue, Adjusted EBITDA, and Free Cash Flow, while Digital Health ARR surged 97% YoY to $105.5M. The mixed results reflect strong top-line growth and a favorable mix shift toward advanced imaging, offset by GAAP earnings pressure from acquisition costs and Digital Health investments.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $622.7M (+25% YoY) vs consensus $609.3M (beat by 2.2%)
- GAAP diluted EPS $0.10 vs consensus $0.20 (miss of 50%)
- Adjusted EBITDA $99.7M (+22.7% YoY), a quarterly record
- Digital Health ARR $105.5M at June 30, 2026, up 97.2% YoY and 8.9% sequentially
- Imaging Center guidance raised: revenue $2,370-$2,420M, Adj. EBITDA $345-$358M, FCF $115-$125M
- Digital Health segment revenue $32.4M (+56.5% YoY) but Adj. EBITDA declined to $2.5M from $3.4M due to growth investments
- Advanced imaging mix improved to 29.9% of procedural volumes (up 238 bps YoY)
- Cash balance $726.3M; Net Debt to Adj. EBITDA ratio 1.8x
Financial Impact
Revenue beat by ~$13.4M (2.2%) and guidance raised by $15M at midpoint; GAAP EPS miss of $0.10 vs $0.20 consensus represents a $0.10 shortfall.
Risk Factors
- Digital Health segment investments may continue to pressure near-term margins and GAAP profitability
- Integration of $315.7M in acquisition spending during H1 2026 could dilute returns if synergies lag
- Debt increased to $1.33B (net of cash) from $1.06B at year-end 2025, raising interest expense risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341500 |
Track record
21 reports on RDNT
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +26.65% at T+60 after the Jun 25, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $76.04 Now $76.89 +1.12% settles Feb 10
- Nov 9, 20267d ago 8-K Bullish 6/10 No price data
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $78.38 Now $76.89 −1.90% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $73.54 Now $76.89 +4.56% settles Jan 26
- Oct 26, 202621d ago 8-K Neutral 6/10 Entry $73.54 Now $76.89 +4.56% settles Jan 25
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $73.54 Now $76.89 +4.56% settles Jan 25
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $67.70 Now $76.89 +13.57% settles Dec 28
- Aug 10, 202614w ago 8-K Bullish 6/10 No price data
- Aug 9, 202614w ago Press Release Mixed 6/10 Viewing Entry $77.28 to $73.18 Now $76.89 −0.50% ▼ −5.31% −2.89% vs SPY
- Jun 25, 202620w ago Press Release Bullish 5/10 Entry $60.01 to $76.00 Now $76.89 +28.13% ▲ +26.65% +22.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers